lt;0.001) between V1 a V3, a mild enlargement of left atrium (37.1±5.85 to 38.2±5.65mm; p=0,021) and nonsignificant trend to impairment of left ventricle diastolic dysfunction. There was a mild change of pulmonary artery systolic pressure (24.7±7.92 to 27.5±6.97mmHg; p=0,038). Conclusion: Despite many information regarding cardiac impairment of SARS-CoV-2 our study does not suggest increased risk of development of heart failure during the one year follow-up. Based on our results the routine echocardiography and biomarkers collection is currently not recommended after COVID-19 recovery.